US FDA Expediting ANDA Postapproval Manufacturing Changes Due To COVID-19 Impacts

 
• By Sue Sutter
  
To do list conceptual
Nonindustry stakeholders shared their GDUFA III 'to do' list with FDA and generic drug companies. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics